Interestingly, mono-therapeutic treatment with the MCL-1-specific BH3-mimetic VU661013 slowed the growth of HCC1187 and BT20 TNBC xenografts, and co-treatment with docetaxel or doxorubicin further enhanced the inhibition of tumor growth [115]. Here, MCL1 is linked to neoplasm.